{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:41:39Z","timestamp":1783122099104,"version":"3.54.6"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104793","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T16:35:56Z","timestamp":1685723756000},"page":"104793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: A case series and review of the literature"],"prefix":"10.1016","volume":"77","author":[{"given":"Sepideh","family":"Paybast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Nahayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Navardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104793_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-Zoster virus infections in patients treated with fingolimod","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104793_bib0002","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.msard.2023.104793_bib0003","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","article-title":"Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation \u2013 A systematic review of randomized trials, observational studies and case re","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2023.104793_bib0004","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and Varicella Zoster virus infections in natalizumab-treated patients","volume":"57","author":"Fine","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2023.104793_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019598","article-title":"Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets","volume":"14","author":"Gold","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104793_bib0006","first-page":"s159","article-title":"Current and emerging treatment of multiple sclerosis","volume":"22","author":"Hart","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.msard.2023.104793_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax082","article-title":"Safety of live vaccines on immunosuppressive or immunomodulatory therapy\u2014a retrospective study in three Swiss travel clinics","volume":"25","author":"Huber","year":"2018","journal-title":"J. Travel Med."},{"key":"10.1016\/j.msard.2023.104793_bib0008","doi-asserted-by":"crossref","first-page":"e726","DOI":"10.1212\/NXI.0000000000000726","article-title":"Risk of MS relapse after yellow fever vaccination","volume":"7","author":"Huttner","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2023.104793_bib0009","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1177\/1352458515576984","article-title":"Serological evidence of increased susceptibility to Varicella-Zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis","volume":"21","author":"Kohlmann","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104793_bib0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104793_bib0011","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104793_bib0012","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jnnp-2021-326839","article-title":"Vaccination and multiple sclerosis in the era of the COVID-19 pandemic","volume":"92","author":"Monschein","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104793_bib0013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neurol.2019.08.012","article-title":"What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature","volume":"176","author":"Pourcher","year":"2020","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2023.104793_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2023.104793_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104793_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa235","article-title":"Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit\u2013risk assessment for natalizumab","volume":"28","author":"Schwob","year":"2021","journal-title":"J. Travel Med."},{"key":"10.1016\/j.msard.2023.104793_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12348-016-0095-y","article-title":"Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab","volume":"6","author":"Sood","year":"2016","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.msard.2023.104793_bib0018","doi-asserted-by":"crossref","unstructured":"Stokmaier D., Winthrop K., Chognot C., Evershed J., Manfrini M., McNamara J., Bar-Or A., 2018. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis (S36. 002).","DOI":"10.1212\/WNL.90.15_supplement.S36.002"},{"key":"10.1016\/j.msard.2023.104793_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/2051013616655980","article-title":"Efficacy of varicella (VZV) vaccination: an update for the clinician","volume":"4","author":"Wang","year":"2016","journal-title":"Ther. Adv. Vaccines"},{"key":"10.1016\/j.msard.2023.104793_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.161","article-title":"Natalizumab and progressive multifocal leukoencephalopathy","volume":"67","author":"Warnke","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104793_bib0021","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","article-title":"Vaccination in multiple sclerosis: friend or foe?","volume":"10","author":"Zrzavy","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300295X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300295X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:08:58Z","timestamp":1737641338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482300295X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":21,"alternative-id":["S221103482300295X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104793","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: A case series and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104793"}}